The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men

What Was Tested

This randomized controlled trial paper looks at Tesofensine (non-peptide).

Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs.

It inhibits the presynaptic reuptake of the neurotransmitters noradrenaline, dopamine and serotonin, and is thought to enhance the neurotransmission of all three monoamines.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, men only.

Twenty-four-hour energy expenditure (24-h EE), fat oxidation and spontaneous physical activity were measured in a respiration chamber before and after treatment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tesofensine (non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Tesofensine (non-peptide).

A placebo (an inactive look-alike) gave the Tesofensine (non-peptide) group a baseline to be compared against.

They were instructed to maintain habitual food intake and physical activity throughout.

Body composition was assessed by dual-energy X-ray absorption and appetite was evaluated by visual analogue scales in conjunction with a standardized dinner.

What Was Measured

Topics PubMed links to this paper include Appetite, Bridged Bicyclo Compounds, Heterocyclic, Energy Metabolism, Neurotransmitter Uptake Inhibitors, Obesity and Overweight.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesofensine (non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (International journal of obesity (2005)), a journal based in England.

More context: the Tesofensine (non-peptide) compound page, all human trials.